

Original Research Article

Efficacy of **METFORMIN** alone versus its Combination with **SIMVASTATIN** in the Management of Polycystic Ovary

ABSTRACT

Aims: To compare the effectiveness of treatment with **METFORMIN** alone and with a combination of **METFORMIN** and **SIMVASTATIN** in the management of polycystic ovarian syndrome.

Study design: Randomized Clinical Trial.

Place and Duration of Study: Department of Obstetrics and Gynecology (Infertility Unit) at District Headquarter (DHQ) Teaching Hospital, Sahiwal (Pakistan) during June to September, 2018.

Methodology: 162 patients were randomly divided into **METFORMIN** group (n=81) and **METFORMIN** plus **SIMVASTATIN** group (n=81), detailed clinical history, including menstrual details, was taken with thorough examination performed. Baseline ultrasound was performed to evaluate ovarian size and these were considered enlarged with volume >10cc or with >12 follicles in any one ovary. Blood samples were taken at baseline and after three months of

therapy to determine the LH/FSH ratio and lipid profile. Efficacy was defined as >15% decrease in the baseline values.

Results: The mean age of the patients was 27.12 ± 8.17 years and the mean BMI was 24.21 ± 2.2 Kg/m². Efficacy was achieved in 67.1% patients with METFORMIN alone, while in 92.6% with combination medication (p=0.0068).

Conclusion: Managing the women having PCOS with the combination of METFORMIN and SIMVASTATIN is more beneficial as compared to treatment with METFORMIN alone.

Keywords: Polycystic Ovarian Syndrome; PCOS; METFORMIN; SIMVASTATIN.

1. INTRODUCTION

Polycystic ovarian syndrome (PCOS) is common in about 10% of females of reproductive age group [1] and is the most common condition seen by the gynecologists. PCOS is related to hyper-androgenism, ovulatory dysfunction, and Polycystic Ovary (PCO) morphologically [2]. Other common associations of PCOS are obesity, menstrual irregularity, insulin resistance, and infertility. The patients are at an increased risk of abnormal lipo- proteins, hypertension, and cardiovascular and cerebrovascular morbidities [3, 4].

The specific causative agents of PCOS are not clear and heterogeneous nature of syndrome is observed. It seems that it is developed due to accumulation of different diseases sharing several pathophysiological characteristics [5]. Treatment of a patient with PCOS includes lifestyle modifications and pharmaceutical interventions, like oral contraceptives, antiandrogen therapy and blood glucose lowering medicines which in turn lead to decreased stimulation of insulin producing cells, hence lowering the levels of insulin and other androgenic hormones. METFORMIN is usually prescribed in females with PCOS. The resolution of PCOS with METFORMIN can be stimulated further with the addition of medicine, like SIMVASTATIN, which also decreases the ratio of Luteinizing Hormone (LH) to Follicle Stimulating Hormone (FSH) or what we call LH/FSH ratio. Therapy with METFORMIN and SIMVASTATIN is already in use for the aforementioned conditions [6, 7].

METFORMIN is a biguanide which decreases insulin resistance and increase chances of ovulation and pregnancy, followed by declined insulin and androgen levels. **SIMVASTATIN** is a 3-hydroxy-3-methyl glutaryl co-enzyme A reductase inhibitor. It restricts the cholesterol bio-synthesis. **SIMVASTATIN** has antioxidant, anti-inflammatory and anti-androgenic properties. It inhibits the proliferation and steroidogenesis of the ovarian theca interstitial cells [6]. Some clinical trials so far have evaluated the effects of combination of **SIMVASTATIN** and **METFORMIN** with monotherapy of **METFORMIN** only.

Keeping in view the paucity of ample evidence on these two agents and their role in the management of women with PCOS, the objective of this study was to compare the efficacy of **METFORMIN** alone versus **METFORMIN** plus **SIMVASTATIN** in the management of women with polycystic ovarian syndrome.

2. METHODOLOGY

A randomized clinical trial was carried out, during June 2018 to September 2018, in the Department of Obstetrics and Gynecology (Infertility Unit) at District Headquarter (DHQ) Teaching Hospital, Sahiwal which is a district level tertiary care healthcare facility in Pakistan. Approval from the ethical committee of the hospital was followed by inclusion of patients who presented during June and July 2018 based on following criteria:

2.1. Inclusion Criterion

- Female patients of reproductive age group (18-45 years).
- Patients presenting Polycystic ovarian (PCO) endocrinopathy and having any two of the following;
 - o Signs of hyperandrogenism
 - o Ovulatory dysfunction / Menstrual abnormalities and irregularities

- o PCO morphology confirmed on Ultrasonography (USG)

2.2. Exclusion Criteria

- Patients who were having any other endocrine abnormality or patients with any chromosomal anomaly (e.g. Turner Syndrome)
- Patients with any form of liver or kidney disease.
- Patients who were taking any kind of exogenous hormones.
- Patients who were on any form of pharmacologic contraception.
- Patients who didn't consent to inclusion in the study.

A sum of 162 patients were selected for the sake of this study after calculation of sample size in the population of Sahiwal District (Sahiwal District has 381,468 females of reproductive age) using WHO sample size calculator for Bio Medical research and studies by taking 95% confidence level with 5% margin of error and considering the expected decrease in total cholesterol levels with **METFORMIN** alone to be 4.2%, and expected decrease in total cholesterol levels with **SIMVASTATIN** and **METFORMIN** to be 29.5%. Patients were further divided into two groups by systematic random sampling technique. Group-A (n=81) was the control group and was treated with **METFORMIN** alone while Group-B (n=81) was the interventional group and was given **SIMVASTATIN** in addition to **METFORMIN**.

Informed consent was taken from the patients fulfilling the inclusion criteria. The study patients were selected from both the in-patient and the out-patient departments of the study center. Detailed clinical history, including menstrual details, was taken along with thorough clinical examination performed. Baseline ultrasound was performed to evaluate ovarian size which were considered enlarged with volume more than 10 cc or with more than 12 follicular cysts (size of 2-9 mm) in any one ovary. A baseline intravenous blood sample was taken, by using a 5cc syringe and stored in sterile vials to

determine the LH/FSH ratio and lipid profile. These were done at Department of Pathology, Sahiwal Medical College, Sahiwal.

LH and FSH levels were determined on Cobas 411 by electro chemiluminescence and lipid profile was done on Hitachi 902. The reports were verified by in-house hematologist. The patients in group-A were treated with oral METFORMIN (500 mg thrice daily) while patients in group-B received oral METFORMIN (500mg thrice daily) plus SIMVASTATIN (20 mg once daily at night). Then patients were followed up in OPD for 3 months with continuation of trial therapy. After three months, blood sample was again obtained to determine the LH/FSH ratio and lipid profile. Reports were assessed and efficacy was labelled, if there was >15% decrease in levels of lipid profile and LH/FSH ratio.

All information was gathered on a specifically designed Performa and Version 21 of the software Statistical Package for Social Sciences (SPSS) was used to analyze all this data. Efficacy, being a nominal data, was analyzed as frequency along with percentage and was subjected to Chi-square test. While the quantitative data like age, baseline cholesterol, LH/FSH ratio, and BMI was represented as mean along with its standard deviation. P value below 0.05 was considered significant statistically, for the purpose of this study.

3. RESULTS

The mean age of the patients was 27.12 ± 8.17 years. In this study, the mean BMI was 24.21 ± 2.2 Kg/m². The mean LH/FSH ratio at baseline of the patients was 3.54 ± 1.21 . The mean LH/FSH ratio at the third month of the patients was 2.24 ± 1.08 . The mean total cholesterol value at baseline was 251.84 ± 36.20 mg/dL. The mean total cholesterol value at the third month was 163.83 ± 12.62 mg/dL.

Table I: Comparison of Efficacy in both the Groups stratified based upon LH/FSH ratio

LH/FSH at Baseline	Group A	Group B	P-Value*
Efficacy (Yes / No)	(METFORMIN only Group)	(Interventional Group)	
≤3			
Yes	24	37	0.039
No	22	06	
≥3			
Yes	30	38	0.08
No	05	0	
*Pearson Chi-Square test			

Efficacy was achieved in 129 patients, out of whom 54 belonged to group A and 75 were from group B. Efficacy in patients having LH/FSH ratio below 3 at baseline was achieved in 61 cases; in which, 24 were from group A and 37 were from group B (Table I). Similarly, the efficacy in patients having LH/FSH ratio above 3 at baseline was achieved in 68 cases, in which 30 were from group A and 38 were from group B. Statistically, a significant difference was found between the study groups and efficacy in patients having LH/FSH ration below 3, i.e. p=0.039.

Table II: Comparison of Efficacy in both the Groups stratified by Total Cholesterol level			
Total Cholesterol	Group A	Group B	P-Value*

Efficacy (Yes / No)	(METFORMIN only Group)	(Interventional Group)	
≤220 mg/dL			
Yes	29	26	0.061
No	10	01	
≥220 mg/dL			
Yes	23	52	
No	19	02	0.042
*Pearson Chi-Square test			

Table II shows that efficacy was achieved in 55 patients having less than 220 mg/dL total cholesterol value at baseline, among whom 29 were from group A and 26 were from group B. Efficacy was achieved in 75 patients having above 220 mg/dL total cholesterol value at baseline, out of whom 23 were from group A and 52 were from group B. Statistically, there was significant difference found between the study groups and efficacy in patients having total cholesterol value above 220 mg/dL, i.e. $p=0.042$. Overall efficacy was achieved in 79.6% cases. In Group A the efficacy was 67.1% while 92.6% efficacy was observed in Group-B where patients were given combination treatment ($p=0.0068$).

Data was also stratified for age. In age <30 years, efficacy was achieved in 30 (61.8%) with METFORMIN, while in 39 (92.9%) with combination. In age >30 years, efficacy was achieved in 22 (75%) with METFORMIN, while in 37 (92.3%) with combination.

4. DISCUSSION

PCOS is a complex disorder. It is described as raised androgen levels, irregular menstrual cycle, or cysts of small size in one or both side ovaries [8]. It affects at least 7% of females of reproductive age group [9]. According to National Institute of Health, the syndrome develops in about five million females capable of reproduction. About 5-10% females aged 18-44 years develop PCOS. Thus it becomes the most common endocrine anomaly in females of reproductive age group [10].

In this study, desired efficacy was achieved in 129 (79.63%) cases. Efficacy was 67.1% among the patients treated with METFORMIN alone while 92.6% where combination of METFORMIN and SIMVASTATIN was administered. There was significant difference between both groups. Not much data was published on this topic in literature. However, some of the previous studies are discussed below.

Banaszewska et al. included 113 subjects in their study. With SIMVASTATIN alone, androgenic hormones reduced significantly. But LH or FSH did not decrease either with SIMVASTATIN or METFORMIN alone or in combination. Total cholesterol and low-density lipoprotein also reduced significantly with SIMVASTATIN and combination of SIMVASTATIN and METFORMIN. The number of menstruations increased and ovarian volume decreased more in patients taking SIMVASTATIN. They concluded that SIMVASTATIN has better outcome than METFORMIN, but the combination of SIMVASTATIN and METFORMIN and SIMVASTATIN alone almost had equal results [6].

Experimental trials showed that METFORMIN can help in reduction of androgen levels significantly, increase insulin sensitivity and stimulate weight loss in females having PCOS. One trial proposed that METFORMIN, if used during pregnancy, has nine times reduction in risk of gestational diabetes in pregnant females with PCOS. As well as, along with prevention from gestational diabetes in pregnant females having PCOS, METFORMIN can also decrease the chance of preeclampsia in these females [11]. Gestational diabetes and preeclampsia usually develop due to deranged levels of lipid profile. So, SIMVASTATIN can help in controlling lipid levels and preventing derangement of these levels and thus improves the chances of conception and reduces the risk of gestational diabetes mellitus and preeclampsia.

A longitudinal study proposed that METFORMIN can also help boost up the metabolic system of females with PCOS, if given as 36 months treatment; especially it improves high-density lipoprotein in blood, diastolic blood pressure and BMI.

But insufficient data is available, which could recommend the prescription of METFORMIN to all females having PCOS [12].

On flip side of the coin, the study conducted by Carrick demonstrated that the SIMVASTATIN therapy for patients with PCOS appears to possibly result in significant decreases in testosterone levels, and therefore reduce the clinical signs of PCOS. However, SIMVASTATIN plus METFORMIN therapy does not provide much, if any, additional reduction in metabolic parameters [13].

A study by Kazerooni et al. revealed that combination of SIMVASTATIN and METFORMIN decreased total cholesterol more than 15% from baseline by 29.5% versus 4.2% with METFORMIN and placebo after 3 months of therapy. LH/FSH ratio significantly decreased by 38.3% and increased by 4.4% after 3 months of therapy with METFORMIN plus SIMVASTATIN and METFORMIN plus placebo, respectively [1]. Other meta-analysis and systematic reviews proposed that in females with PCOS having a particular category, METFORMIN can help improve reproductive function regardless of insulin resistance and glucose intolerance [14]. METFORMIN can also help in reducing significantly liver fat indicators in obese females having PCOS [15].

There is deficiency of evidence regarding the efficacy of SIMVASTATIN and METFORMIN combination therapy for PCOS. Larger trials are needed for prolonged period and large sample size to get more evidence regarding beneficial aspects of combination of SIMVASTATIN plus METFORMIN and also side effects, if any.

4. CONCLUSION

The combination of METFORMIN plus SIMVASTATIN group showed more efficacious results as compared to METFORMIN alone in treatment of polycystic ovarian syndrome patients. So the combination of METFORMIN plus SIMVASTATIN is a better choice for treatment of PCOS in comparison with METFORMIN alone but a lot more research is needed to explore this topic further.

REFERENCES

1. Kazerooni T, Shojaei-Baghini A, Dehbashi S, Asadi N, Ghaffarpasand F, Kazerooni Y. Effects of **METFORMIN** plus **SIMVASTATIN** on polycystic ovary syndrome: a prospective, randomized, double-blind, placebo-controlled study. *Fertil Steril* 2010; 94:2208-13.
2. Lindholm Å, Andersson L, Eliasson M, Bixo M, Sundström-Poromaa I. Prevalence of symptoms associated with polycystic ovary syndrome. *International J Gynecol Obstet* 2008; 102: 39-43.
3. Wild RA, Carmina E, Diamanti-Kandarakis E, Dokras A, Escobar-Morreale HF, Futterweit W, et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. *J Clin Endocrinol Metab* 2010; 95:2038-49.
4. Repaci A, Gambineri A, Pasquali R. The role of low-grade inflammation in the polycystic ovary syndrome. *Mol Cell Endocrinol* 2011; 335 :30-41.
5. Banaszewska B, Pawelczyk L, Spaczynski RZ, Duleba AJ. Effects of **SIMVASTATIN** and **METFORMIN** on polycystic ovary syndrome after six months of treatment. *J Clin Endocrinol Metab* 2011; 96:3493-501.
6. Banaszewska B, Pawelczyk L, Spaczynski RZ, Duleba AJ. Comparison of **SIMVASTATIN** and **METFORMIN** in treatment of polycystic ovary syndrome: prospective randomized trial. *J Clin Endocrinol Metab* 2009; 94:4938-45.
7. Sharma D, Dahiya K, Dora A, Ghalaut VS. Effect of rosiglitazone in spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome. *J Gynecol Surg* 2006; 22:151-6.
8. Umland E, Weinstein L, Buchanan E. Menstruation-related disorders. Pharmacotherapy: A pathophysiologic approach based on: DiPiro JT, Talbert RL, Yee GC, et al, eds. *Pharmacotherapy: A pathophysiologic approach* 8th ed. New York, NY: McGraw-Hill 2011.
9. Aubuchon M, Legro RS. Polycystic ovary syndrome: Current infertility management. *Clin Obstet Gynecol* 2011; 54:675-84.
10. Care IoLARCo, Animals UoL, Resources NloHDoR. Guide for the care and use of laboratory animals: National Academies; 1985.
11. Richard Scott Lucidi. Polycystic ovarian syndrome. 2014 [cited 2015]; Available from: <http://emedicine.medscape.com/article/256806-overview>.
12. Cheang KI, Huszar JM, Best AM, Sharma S, Essah PA, Nestler JE. Long-term effect of **METFORMIN** on metabolic parameters in the polycystic ovary syndrome. *Diab Vasc Dis Res* 2009; 6:110-9.
13. Carrick E. The use of **SIMVASTATIN** plus **METFORMIN** therapy in patients with polycystic ovarian syndrome. Pacific University Common Knowledge; 2012.

14. Gambineri A, Pelusi C, Manicardi E, Vicennati V, Cacciari M, Morselli-Labate AM, et al. Glucose intolerance in a large cohort of Mediterranean women with polycystic ovary syndrome phenotype and associated factors. *Diabetes* 2004; 53:2353-8.
15. Rizzo M, Berneis K, Carmina E, Rini GB. How should we manage atherogenic dyslipidemia in women with polycystic ovary syndrome? *Am J Obstet Gynecol* 2008; 198:e1-5.

DEFINITIONS, ACRONYMS, ABBREVIATIONS

DHQ: District Headquarters

FSH: Follicle Stimulating Hormone

g/dL: gram per deci-litre

LH: Luteinizing Hormone

PCO: Polycystic Ovary (Ovarian)

PCOS: Polycystic Ovarian Syndrome

SD: Standard Deviation

SPSS: Statistical Package for Social Sciences